Quick Facts: Approved Therapeutic Domains

• Management of excessive sleepiness associated with narcolepsy.
• Intervention for excessive sleepiness due to obstructive sleep apnea.
• Support for wakefulness in patients with shift work disorder.

---

Modafinil is a prescription medication utilized to improve wakefulness in adult patients experiencing excessive daytime sleepiness (EDS) resulting from specific chronic sleep disorders. It is an established option for the management of EDS associated with narcolepsy, a condition characterized by sudden, overwhelming urges to sleep.

The medication is also indicated as an adjunctive therapy for EDS related to obstructive sleep apnea (OSA). For patients with OSA, the use of this compound does not replace primary treatment options, such as continuous positive airway pressure (CPAP), which should be maintained throughout the treatment period.

Furthermore, the compound may be utilized to address the excessive sleepiness experienced by individuals with shift work disorder (SWD), assisting them in maintaining wakefulness during scheduled work hours.

Modafinil Arrow is approved exclusively for adult patients (18 years and older). Use is not recommended in the pediatric population due to safety and effectiveness concerns documented in regulatory reviews.

The medicine is contraindicated and must not be used in individuals with a known hypersensitivity to modafinil or armodafinil. Absolute exclusion also applies to patients with pre-existing conditions such as uncontrolled moderate to severe hypertension or cardiac arrhythmias. Regulatory documents state that use is not recommended in patients with a history of Left Ventricular Hypertrophy (LVH) or cor pulmonale.

Use is highly conditional for several populations. Patients with severe hepatic impairment are subject to an official regulatory requirement for a mandated dose reduction by one-half. Caution is advised for those with a history of psychiatric disorders (e.g., psychosis, mania, depression) or substance abuse.

The drug must not be used by women who are pregnant or may become pregnant. Females of childbearing potential are required to use effective non-hormonal contraception during treatment and for two months following discontinuation, as regulatory data indicates the compound may reduce the efficacy of hormonal contraceptives. Use is not recommended while breastfeeding.

Modafinil interacts with several medicinal product categories, primarily by altering the activity of certain liver enzymes. These interactions can affect the concentration and effectiveness of other medicines in the body.

Interacting Product Category	Mechanism and Clinical Impact
Hormonal Contraceptives (e.g., combined oral pills, implants)	Modafinil is a moderate inducer of the enzyme CYP3A4/5. This can accelerate the breakdown of hormonal contraceptives, potentially reducing their effectiveness. Alternative or concomitant non-hormonal contraception methods are recommended during treatment and for two months after stopping Modafinil.
Anticoagulants (e.g., Warfarin)	Modafinil may inhibit the enzyme CYP2C9. This could decrease the clearance of warfarin, leading to increased exposure and an elevated risk of bleeding. Prothrombin times/INR should be closely monitored, especially during the first two months of therapy and following dosage changes.
CYP2C19 Substrates (e.g., Diazepam, Phenytoin, Omeprazole)	Modafinil and its metabolites are reversible inhibitors of CYP2C19. Co-administration may decrease the clearance of these drugs, leading to increased systemic levels and potential toxicity, requiring careful dose reduction and monitoring.
Other CNS Stimulants (e.g., Methylphenidate)	The combination may result in additive effects, such as increased heart rate and blood pressure, necessitating caution.

Other drugs metabolized by CYP3A4, such as Cyclosporine and Triazolam, may also have their exposure reduced due to Modafinil's induction effect. Potent CYP inducers like Carbamazepine may, conversely, reduce Modafinil's own plasma levels.

Modafinil's principal action involves binding as a competitive inhibitor to the dopamine transporter (DAT) on presynaptic neuron terminals, particularly in vigilance-regulating regions of the central nervous system. This interaction blocks the reuptake of dopamine from the synaptic cleft, leading to an increased concentration and duration of dopaminergic signaling at postsynaptic receptors.

Beyond this primary mechanism, the compound exhibits complex modulation across multiple neurotransmitter systems. It has been shown to increase extracellular levels of norepinephrine and histamine in the hypothalamus, contributing to its system-level physiological modulation. Furthermore, Modafinil indirectly influences orexin/hypocretin pathways, potentially enhancing activity in these wake-promoting neurons located in the lateral hypothalamus. It also activates glutamatergic circuits while simultaneously inhibiting the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), leading to a net increase in neuronal excitability and arousal state.

Official Administration Guidelines

Modafinil Arrow is administered as an oral tablet, which is the singular approved route of use. The medication is officially available in strengths of 100 mg and 200 mg. The typical daily dose is 200 mg for all approved indications, including narcolepsy, obstructive sleep apnea (OSA), and shift work disorder (SWD).

The administration schedule is strictly once daily and must be tailored to the patient’s condition. For the management of excessive sleepiness associated with narcolepsy and OSA, the dose is taken in the morning. Conversely, for SWD, the single daily dose should be taken approximately one hour prior to the start of the scheduled work shift. The tablet may be swallowed with or without food, as food intake does not significantly affect overall drug absorption.

Specific use rules apply to certain populations. For individuals with severe hepatic impairment, the dosage must be reduced by half to 100 mg per day. Furthermore, the medication is not recommended for use in pediatric patients under 18 years of age. In cases of a missed dose for scheduled morning administration, the standard procedural instruction is to skip the missed dose and resume the regular schedule the next day. In the context of OSA, the medicine serves only as adjunctive therapy and must be used in continuation with the primary treatments, such as Continuous Positive Airway Pressure (CPAP).

Research Evidence / Overview of Studies for Modafinil Arrow (Moclobemide)

This section provides an objective overview of the official research, including randomized controlled trials (RCTs) and systematic reviews, that was used in research exploring the clinical profile of the active ingredient, Moclobemide. This overview research describes what types of studies was studied for and what patterns were observed in the study populations, without offering clinical advice or treatment recommendations.

---

Evidence for Use in Major Depressive Disorders (MDD)

The core research base for Moclobemide consists of numerous short-term randomized controlled trials (RCTs) and meta-analyses that have studies monitored the short-term response during the acute treatment phase for adult patients with MDD. These studies research examined how symptoms change over time, and studies monitored outcomes related to symptom intensity or variability, typically using standardized scales. Comparisons was studied for against treatments like placebo, Tricyclic Antidepressants (TCAs), and Selective Serotonin Reuptake Inhibitors (SSRIs).

Studies reported that when compared to placebo, measurements of symptom change and response rates showed patterns of change that were more frequently observed among the active treatment groups. Furthermore, comparative trials and meta-analyses data show patterns of clinical response observed when compared to other active antidepressant medications during the initial study period. A research limitation is that some analyses were conducted without a dedicated placebo control group, and the findings primarily reflect the populations studied.

Evidence for Use in Anxiety Disorders

The research base also includes studies that evaluated the treatment for use in certain anxiety conditions, primarily Social Phobia and Panic Disorder, often employing placebo-controlled and active comparative designs.

For Panic Disorder, the evidence has mainly focused on comparative trials where the treatment was evaluated in patients alongside established medications. These comparative studies data show patterns related to symptom outcomes that were consistent with those observed with the active comparator treatments. A key gap is that comparative evidence is lacking from controlled trials that specifically compared the treatment directly against a placebo for this indication.

Common questions about Modafinil Arrow (FAQ)

Q: Why do official documents state Modafinil Arrow is a controlled substance?

Regulatory bodies classify this medication as a Schedule IV controlled substance. This official designation indicates that the drug has a recognized medical use but carries a low potential for abuse or dependence. Official documents note that Modafinil can produce psychoactive effects, which is the rationale for its controlled substance status.

Q: How quickly is Modafinil Arrow described to start having an effect?

According to the drug's official pharmacokinetics information, the medication is rapidly absorbed by the body. Peak plasma concentrations, which reflect the highest concentration of the drug in the bloodstream, are typically reached between 2 and 4 hours after the tablet is taken. Taking the tablet with food may delay the time it takes to reach this peak.

Q: Is Modafinil Arrow considered a stimulant like caffeine?

Modafinil is classified as a wake-promoting agent that acts on the central nervous system. Studies indicate that it has wake-promoting actions similar to certain sympathomimetic agents (stimulants) but that its exact pharmacological profile is not identical to that of typical stimulants like amphetamines. It works by blocking the reuptake of certain neurotransmitters in the brain.

Q: Can older adults use Modafinil Arrow according to official guidelines?

Official product information states that data on the use of Modafinil in patients over 65 years of age is limited. Due to the potential for lower clearance in older adults, official guidelines state that patients in this age group may require a lower daily dose to account for this change in metabolism.

Q: Does Modafinil Arrow have a different effect on the body compared to armodafinil?

Yes, regulatory and clinical pharmacology information points to a difference in the drugs' concentration profiles. Armodafinil is the R-enantiomer, or the longer-lasting component, of the racemic Modafinil mixture. Studies show that armodafinil typically maintains higher plasma concentrations later in the day compared to Modafinil. The difference in plasma concentration profile is a key distinguishing factor noted in the product information.

Q: Are there any known interactions between Modafinil Arrow and common cold medicines?

Official warnings exist regarding co-administration with other Central Nervous System (CNS) stimulants, as this may result in additive effects like increased heart rate or blood pressure. Since some common cold and flu medicines contain CNS stimulants, caution is noted. Modafinil is also known to interact with other drugs metabolized by the CYP450 enzyme system.

Q: How long does the primary effect of Modafinil Arrow usually last?

Based on its pharmacokinetic properties, the effective elimination half-life of Modafinil after multiple doses is approximately 15 hours. This relatively long half-life is described in the product information as supporting the drug's intended duration of action for wakefulness.

Q: How does the drug information describe the long-term use of Modafinil Arrow?

Regulatory guidelines state that the long-term need for the medicine must be periodically re-evaluated by a healthcare professional. This is because clinical trials have not fully evaluated the medication’s efficacy and safety for continuous use beyond a period of nine weeks.

Q: Are there any religious or dietary restrictions mentioned in the drug information for Modafinil Arrow?

Official prescribing information does not list any religious or specific dietary restrictions for this medicine. The administration instructions simply state that the oral tablet may be swallowed with or without food, as food intake does not significantly impact overall drug absorption.

Q: Can Modafinil Arrow affect my ability to drive or operate machinery?

Official labels contain a warning that the drug may affect a person’s judgment or ability to think and react quickly, which could impair the ability to drive or operate machinery. Patients should be aware of how the medicine affects them before engaging in such activities.

Q: Are there any specific tests required before starting treatment with Modafinil Arrow?

Official documentation includes requirements for baseline cardiovascular screening before treatment initiation to check for underlying heart issues. Additionally, ongoing monitoring of blood pressure and heart rate is generally required throughout the course of treatment, as these metrics can be affected by the medication.

Q: Does Modafinil Arrow have a Black Box Warning?

While the official FDA labeling does not contain a formal Black Box Warning, it does include several serious warnings that highlight significant safety risks. These include the potential for life-threatening skin reactions, such as Stevens-Johnson Syndrome, and the risk of psychiatric adverse reactions, such as mania or suicidal ideation.

Q: Are there specific food or drink interactions with Modafinil Arrow?

The official label contains a warning against the concurrent use of alcohol due to its potential interaction. Modafinil can be taken with or without food. Caution is also noted regarding the consumption of caffeine, as this may increase the risk of side effects like nervousness and a fast heartbeat.

Q: What is the risk of dependence or withdrawal associated with Modafinil Arrow?

Modafinil is classified as a Schedule IV controlled substance, which indicates a low potential for abuse and a low risk of physical or mental dependence. It is important to note that the drug can produce psychoactive and euphoric effects; therefore, official caution exists, particularly for patients with a history of substance abuse.

Q: Do regulatory agencies classify Modafinil Arrow as a first-line treatment for excessive sleepiness?

Official administration guidelines explicitly state that the medicine is approved as adjunctive therapy for excessive sleepiness associated with Obstructive Sleep Apnea (OSA). This means it is used in addition to primary treatments. The drug is not approved for use in patients complaining of general fatigue or lack of energy.

Q: Is Modafinil Arrow suitable for individuals with kidney or liver issues?

The product information includes specific guidance for liver (hepatic) impairment: the regulatory label requires a dosage modification for patients with severe liver issues. Caution is also noted for individuals with renal (kidney) impairment due to limited available data on dose adjustments.

How to Store and Dispose of Modafinil Arrow

Modafinil is a Schedule IV Controlled Substance, requiring adherence to official regulatory rules for storage and disposal to maintain product integrity and ensure public safety.

Storage Requirements

Element	Regulatory Requirement
Temperature	Store at controlled room temperature (20 C to 25 C), protected from excess heat.
Protection	Keep in the original container, tightly closed, and away from excess moisture (e.g., not in the bathroom).
Safety	Must be kept in a safe place and out of the sight and reach of children.

Disposal Instructions

Unused or expired Modafinil must be discarded according to local requirements. The preferred method is using a DEA-authorized drug take-back program or mail-back service. If take-back is unavailable, the tablets must be mixed with an undesirable substance (e.g., dirt, coffee grounds), sealed, and placed in the household trash. The product must not be thrown into wastewater.